them to quickly relay activating signals to the innate and adaptive immune compartment to orchestrate leukocyte migration through tissues or to govern repair processes. 6, 7 Platelets are known to bind HCMV, 8 but the consequences of this interaction and the receptors involved are unknown. HCMV can interact with a plethora of receptors, including integrins and growth factor receptors. 9 HCMV is also sensed by Toll-like receptors (TLRs), a family of pattern recognition molecules that can engage a variety of microbial products and subsequently trigger an inflammatory response. 9 Interestingly, the ligands for host TLRs are viral envelope glycoproteins, which also play key roles in the HCMV entry pathway. 10 Therefore, TLR2, TLR7, and TLR9 form the central basis of the membrane detection machinery for HCMV. 11, 12 Although TLRs were initially thought to be restricted to cells of the innate immune system, it has been revealed recently that the majority of TLRs are also expressed on the surface of platelets. [13] [14] [15] Interestingly, not all platelets express TLRs: 55% to 60% are positive for TLR4, 10% to 40% are positive for TLR9, and only 4% to 16% are positive for TLR2. [14] [15] [16] It was speculated that platelet expression of TLR might be due to the adsorption of free TLR in the plasma. However, megakaryocytes are also positive for TLRs, 14, 17 and platelet TLR1/2, TLR4, and TLR9 have been proven to be functional because they trigger intracellular signaling, resulting in platelet activation. [18] [19] [20] [21] It this study, we show that HCMV induces platelet activation via binding to a TLR2-positive platelet subpopulation, which in turn triggers further platelet activation via release of platelet granule content (eg, ADP), which results in proinflammatory and proangiogenic responses. Thus, HCMV-platelet interactions are likely to exacerbate tissue damage and contribute to atherogenesis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

HCMV Bound Platelets via TLR2
HCMV-receptor interactions seem to be cell-type specific.
To determine which platelet receptors bind HCMV, we added purified, ultraviolet-inactivated virus strain VR1814 to whole blood and measured virus-cell interactions. 1.9% of blood cells and 1.8% of all platelets bound HCMV (Figure 1 ). Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and TLR2 have been reported to bind HCMV, and as platelets are known to express both receptors, we analyzed whether either were involved in platelet-HCMV interactions. 1.1% of all blood cells were positive for DC-SIGN, whereas 52.4% of the HCMV-positive cells were DC-SIGN positive (Figure 1 ). 0.7% of platelets were positive for DC-SIGN, whereas the HCMV-positive platelets of 32.1% were DC-SIGN positive ( Figure 1 ). Blood cells of 2.1% were positive for TLR2, whereas the HCMV-positive cells of 90.5% were also TLR2 positive. Platelets of 1.9% were positive for TLR2, whereas the HCMV-positive platelets of 91.4% were positive for TLR2 ( Figure 1 ). These results imply that HCMV predominantly binds to TLR2-positive platelets.
HCMV Induced Platelet Activation via TLR2
We then determined whether HCMV-platelet interactions induced platelet activation. As depicted in Figure 2A , the lowest concentration of HCMV sufficient to induce a significant increase in platelet surface expression of P-selectin was 1×10 6 HCMV particles/mL. Platelet activation in response to HCMV was a rapid process because a significant increase in platelet surface expression of P-selectin could be already observed after 5 minutes of stimulation and a plateau was reached at 10 minutes of incubation ( Figure 2B ). HCMV-induced surface expression of P-selectin was completely abolished in the presence of a TLR2-blocking antibody or the phosphoinositide 3-kinase inhibitor LY294002 ( Figure 2B ). In line with these results, HCMV-treated platelets also had increased AKT, p38, and extracellular signal-regulated kinase (ERK) phosphorylation, with less pronounced effects in platelets that were treated with a blocking TLR2 antibody ( Figure 2C ). Although only 1% to 3% of platelets were positive for TLR2 and bound HCMV, 12% to 22% became activated in response to HCMV ( Figure 2B ). Analysis of murine TLR2 −/− platelets revealed that platelets lacking TLR2 were unable to respond to murine CMV (MCMV), although platelet supernatant from wild-type mice was able to trigger platelet activation even in TLR2 −/− mice ( Figure 2D ). This indicated that in response to CMV platelets release mediators that result in further platelet activation. We then tested whether ADP/ATP release was responsible for the observed effects. Indeed, we found that apyrase or ADP receptor antagonists abrogated HCMV-mediated platelet activation ( Figure 2E ).
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To further prove that soluble mediators released from HCMV-treated platelets can activate human platelets, we stimulated TLR2-inhibited platelets with the supernatant of HCMV-treated platelets in the presence or absence of apyrase or ADP receptor antagonists ( Figure 2F ). In line with results from CMV stimulation of murine platelets, the supernatant of HCMV-treated human platelets was able to activate platelets in the absence of a functional TLR2 receptor ( Figure 2F ). This effect was abrogated in the presence of apyrase or ADP receptor antagonists ( Figure 2F ). From these data, we conclude that HCMV binds to and activates human platelets via a TLR2-dependent mechanism.
Platelet Activation by HCMV Did Not Induce Platelet Adhesion or Aggregation
To determine whether HCMV modifies platelet adhesion, we measured platelet adhesion to a collagen-coated surface under high shear stress in whole blood. As shown in Figure 3A , platelet adhesion and aggregate formation were not enhanced by HCMV treatment. We then analyzed the effects of HCMV on platelet aggregation using light transmission aggregometry. As shown in Figure 3B , platelet aggregation was not enhanced in response to HCMV stimulation. Platelet stimulation with HCMV-treated neutrophil supernatant did not result in platelet aggregation either ( Figure 3B ). We then examined whether platelets provide a more procoagulant surface in response to HCMV stimulation by testing the levels of the procoagulant phosphatidylserine, but no significant increase could be observed ( Figure 3C ). We then examined whether plateletfibrinogen binding was affected by HCMV treatment using A, Human platelets (3×10 8 /mL) were stimulated with different concentrations of HCMV (1×10 5 -10 9 /mL) and surface expression of CD62P determined by flow cytometry. B, Human platelets (3×10 8 /mL) in the presence and absence of a blocking anti-Toll-like receptor (TLR) 2 antibody (25 μg/mL) or LY294002 (20 μmol/L) were stimulated with HCMV (1×10 8 /mL) and surface expression of CD62P determined by flow cytometry. Means and SDs from 5 independent experiments. C, Western blots of phosphorylated (p-AKT, p-p38, p-ERK) and total proteins (AKT, p38, ERK) of platelets (3×10 8 /mL) stimulated with HCMV (3×10 8 / mL) for 10 minutes in the presence and absence of a blocking anti-TLR2 antibody (25 μg/mL). One typical Western blot of 3 independent experiments. D, Platelets from wild-type and TLR2 −/− mice (3×10 8 / mL) were stimulated with murine CMV (MCMV; 1×10 8 /mL) or supernatant from MCMV-stimulated platelets and surface expression of CD62P determined by flow cytometry. Means and SDs from 3 independent experiments. E, Human platelets (3×10 8 /mL) in the presence and absence of apyrase (10 U/mL) or P2Y1 inhibitor MRS2179 (10 μmol/L) and P2Y12 inhibitor MRS2159 (10 μmol/L) were stimulated with HCMV (1×10 8 /mL) and surface expression of CD62P determined by flow cytometry. One typical dot plot of 3 independent experiments. F, Platelets were preincubated with anti-TLR2 (25 μg/mL) and then stimulated with supernatants from HCMV-stimulated platelets in the presence and absence of apyrase and P2Y1/P2Y12 inhibitors and surface expression of CD62P determined by flow cytometry. One typical dot plot of 3 independent experiments. *P<0.05. FCS indicates forward scatter.
fluorescence labeled fibrinogen but could not detect any significant changes ( Figure 3D ). Based on these data, we conclude that HCMV does not induce procoagulant effects nor can an increase in platelet aggregate formation be observed, suggesting that the action of HCMV on platelets is unlikely to have prothrombotic effects.
Platelets Interact With Different Leukocyte Subsets in Response to HCMV
The initial attachment between platelets and leukocytes is mediated by platelet P-selectin binding to its constitutively expressed leukocyte counter receptor P-selectin glycoprotein ligand-1, resulting in the formation of platelet-leukocyte aggregates. Because HCMV induces surface expression of P-selectin, we analyzed whether this activation could induce the formation of platelet-leukocyte aggregates. The percentage of platelet-positive leukocytes in whole blood significantly increased after HCMV stimulation ( Figure 4A ). These effects were dependent on P-selectin/P-selectin glycoprotein ligand-1 interaction because a blocking antibody against P-selectin (anti-CD62P) completely abolished the formation of these aggregates ( Figure 4A ). Moreover, platelets were unable to bind leukocytes in the presence of a TLR2-blocking antibody. To determine whether TLR2 from platelets or leukocytes was responsible for the observed effects, we incubated platelets with anti-TLR2 and added HCMV-activated leukocytes, or vice versa. As depicted in Figure 4A , inhibition of platelet TLR2 was sufficient to reduce platelet-leukocyte aggregate formation to almost basal levels.
Analysis of leukocyte subpopulations interacting with platelets revealed that the strongest increase in platelet-leukocyte aggregates was found with neutrophils, followed by monocytes and lymphocytes ( Figure 4B ). Analysis of lymphocyte subsets revealed that in response to HCMV only platelet interaction with B cells increased significantly, whereas there was only a trend of increased platelet-T-cell interaction ( Figure 4B ). Analysis of dendritic cell subpopulations revealed that HCMV-activated platelets interacted with both the myeloid and the plasmacytoid dendritic cells ( Figure 4B ).
Platelets Enhanced Neutrophil Activation in Response to HCMV
We then examined the effects of HCMV on neutrophil activation in the presence and absence of platelets. HCMV led to CD11b activation ( Figure 4D ) and enhanced surface expression of CD14 and CD16 and resulted in increased reactive oxygen formation ( Figure 4E ). These neutrophil activating effects were further enhanced by the presence of platelets ( Figure 4D and 4E), indicating that platelets further accelerate neutrophil activation in response to HCMV.
Platelets Enhanced Leukocyte Adhesion and Transmigration in Response to HCMV
To determine whether HCMV and platelets influenced leukocyte adherence and transmigration, neutrophils, with or without platelets, were perfused at a shear rate of 50 s −1 across a tumor necrosis factor-α-treated human umbilical vein endothelial cells (HUVEC) monolayer, in the presence or absence of HCMV. As shown in Figure 5A , treatment of leukocytes with HCMV tended to enhance adhesion to an HUVEC monolayer, whereas in the presence of platelets, HCMV significantly enhanced leukocyte adhesion ( Figure 5A ). In response to stimulation with HCMV, leukocyte transmigration was also significantly enhanced ( Figure 5B ), and this effect was further boosted in the presence of platelets. From these data, we conclude that HCMV induces leukocyte activation, adhesion, and transmigration and that platelets further amplify these processes.
HCMV Stimulated Platelets Released Proinflammatory and Proangiogenic Chemokines
Next, we analyzed surface expression and release of proinflammatory CD40L and interleukin-1 β (IL-1β) and proangiogenic vascular endothelial-derived growth factor (VEGF) release on stimulation with either HCMV or ADP. VEGF was measured after 15 minutes because it is immediately released on platelet degranulation, whereas CD40L is first expressed on the platelet surface followed by shedding, a process which takes minutes to hours. IL-1β can be freshly synthesized and released via microvesicles. Therefore, soluble CD40L (sCD40L) and IL-1β were measured after 2 hours. HCMV and ADP induced surface expression of CD40L after 15 minutes and release of sCD40L and IL-1β after 2 hours, but the effects were more pronounced in ADP-stimulated platelets compared with HCMV stimulation ( Figure 6A-6C) . VEGF rapidly increased in response to HCMV stimulation to a higher extent compared with ADP ( Figure 6D ). As shown in Figure 6E , conditioned supernatant from HCMV-stimulated and ADP-stimulated platelets promoted tube formation, whereas the conditioned supernatant from unstimulated platelets, or HCMV in buffer, had no proangiogenic effect. From these data, we conclude that HCMV triggers the release of proangiogenic and proinflammatory cytokines from platelets.
Cytomegalovirus Induced Platelet Activation and Neutrophil Extravasation In Vivo
To determine whether CMV activated platelets in vivo, we infected mice with MCMV and examined platelet activation in the A, Whole blood (diluted 1:5 in PBS) in the presence and absence of blocking anti-CD62P or anti-Toll-like receptor (TLR) 2 antibody (10 μg/mL for 20 minutes preincubation) was stimulated with HCMV (3×10 8 /mL for 20 minutes) and platelet-leukocyte aggregate formation analyzed; data are mean±SD from 5 experiments (*P<0.05; **P<0.01 vs baseline levels; #P<0.05 vs HCMV activation). p and l indicates that only platelets (p) or leukocytes (l) were treated with anti-TLR2 antibody. B, Subpopulation analysis of HCMV-induced platelet-leukocyte aggregates: neutrophils determined by positivity for CD15, monocytes as CD14 high cells, and lymphocytes by positivity for CD19 (for B cells) and CD3 (for T cells). Myeloid dendritic cells (DCs) were determined as CD1c (BDCA-1) + /CD19 − ) subset and plasmacytoid DCs by positivity for CD303. C, Confocal images of platelet-leukocyte aggregate formation in response to HCMV (3×10 8 /mL for 20 minutes; scale bar, 10 μm). Images are representative of 3 experiments. D, Isolated neutrophils (1×10 6 /mL) were incubated with HCMV (3×10 8 /mL for 20 minutes) in the presence or absence of platelets and CD11b activation (CBRM1/5) analyzed. Data are mean±SD from 5 independent experiments (*P<0.05 **P<0.01 vs baseline levels). E, Isolated neutrophils (1×10 6 /mL) were incubated with HCMV (3×10 8 / mL for 20 minutes) in the presence or absence of platelets and analyzed for positivity of CD14, CD16 expression, and reactive oxygen species (by dihydrorhodamine 123 [DHR123]). Dot plots and histograms are representative of 4 independent experiments. MFI indicates mean fluorescence intensity; and SSC, side scatter. circulation 3 hours after injection. As shown in Figure 7A -7D, no significant difference in platelet-fibrinogen binding ( Figure 7A ) was observed between MCMV and PBS-injected control mice, whereas surface expression of CD40L ( Figure 7B ), plateletleukocyte aggregates ( Figure 7C ), and plasma levels of VEGF ( Figure 7D ) significantly increased. In a thioglycollate-elicited sterile peritonitis model, we can show that MCMV shows a tendency to enhance neutrophil extravasation with effects more pronounced in wild-type compared with TLR2 −/− mice ( Figure 7E ). A similar pattern was observed for IL-6 release ( Figure 7F ). To determine whether platelet TLR2 was involved in these effects, we platelet depleted wild-type mice and transfused them with either TLR2 +/+ or TLR2 −/− platelets, which were ex vivo stimulated with MCMV. As shown in Figure 7G , MCMV stimulation of platelets resulted in in vivo platelet-leukocyte aggregate formation, with effects less pronounced in TLR2 −/− platelets. In line with this observation, also neutrophil recruitment was enhanced slightly in TLR2 +/+ compared with TLR2 −/− platelets ( Figure 7H ).
Discussion
HCMV is released into the blood during active infection, allowing HCMV-platelet interactions. Here, for the first time, we show that HCMV predominately bound to a TLR2-positive platelet subpopulation, leading to the induction of platelet activation through a TLR2-dependent pathway. Platelet activation by HCMV could be completely abolished on blocking TLR2 receptor or inhibition of phosphoinositide 3-kinase signaling, which is a key mediator in TLR2-induced platelet activation. 19 Platelets have been reported previously to express TLR2 on the surface of 4% to 16% platelets. [14] [15] [16] However, in our study, these levels were lower with 1.3% to 3% TLR2-positive platelets, which strongly correlated with the percentage of HCMV-bound platelets. Despite the low percentage of TLR2-positive platelets, ≈20% of platelets became P-selectin positive in response to HCMV, indicating that activation of the TLR2-positive subpopulation triggered further platelet activation in a TLR2-independent fashion. This observation was confirmed by studying murine platelets lacking TLR2, which did not respond to CMV stimulation, whereas the supernatant of CMV-treated wild-type platelets resulted in platelet degranulation even in the absence of a functional TLR2 receptor. We further show that ADP and ATP are involved in this secondary platelet activation because apyrase and ADP receptor antagonists could counteract this secondary activation. ADP release is a crucial cofactor for platelet activation in response to many agonists, which made blocking of the ADP receptor a widely used clinical target to prevent platelet activation. Apyrase has been shown previously to be a potent inhibitor of secondary platelet activation in response to TLR2 activation because it reduced P2X1-evoked calcium signals. 22 Concentrations of 1 million HCMV particles per mL, which corresponds to a HCMV:platelet ratio of 1:300, were sufficient to trigger a significant increase in platelet degranulation.
In organ transplant patients, where HCMV is associated with acute and chronic allograft rejection and vasculopathy, 23 circulating plasma levels of HCMV range between 0 and 30 000 virus copies/mL or ≤8 virus particles per 100 leukocytes, 24 with higher levels at infection sites, making platelet activation in response to HCMV a likely in vivo scenario.
However, HCMV-induced platelet activation did not result in platelet adhesion and aggregation of HCMV-treated platelets under high shear stress to a collagen-coated surface. Nor did HCMV induce surface expression of procoagulant platelet phosphatidylserine or increased fibrinogen binding of platelets.
We show that HCMV-stimulated platelets rapidly formed heterotypic aggregates with leukocytes, through platelet TLR2 signaling and subsequent platelet P-selectin binding to P-selectin glycoprotein ligand-1. Analysis of leukocyte subsets revealed that platelets predominantly interacted with monocytes, neutrophils, as well as with dendritic cells. In the lymphocyte population, only an increase in B-cell-platelet aggregates but not T-cell-platelet aggregates was observed in response to HCMV. Elevated levels of circulating plateletleukocyte aggregates represent a risk factor for cardiovascular disease and are a predictor of acute myocardial infarction 25 because the formation of platelet-leukocyte aggregates is known to promote leukocyte activation, formation of reactive oxygen species, and the exposure of leukocyte tissue factor. 25 Indeed, we show that HCMV led to a rapid activation of neutrophils, resulting in degranulation and reactive oxygen formation, which was more pronounced when platelets were present. On stimulation with HCMV, leukocyte adhesion and transmigration through an endothelial monolayer were elevated and also these processes were further amplified in the presence of platelets. Platelet activation and platelet-leukocyte interaction are a known risk factors for varies pathologies 25 ; however, the in vivo significances of platelet activation and leukocyte activation in response to HCMV need to be addressed in further studies.
HCMV infection modulates the type and quantity of bioactive proteins released from infected cells, 26 and many of these factors play important roles in the pathogenesis of vascular diseases. However, it is currently unknown which factors platelets release in response to HCMV stimulation. Here, we show that platelet-HCMV interaction induced the release of proangiogenic cytokines such as VEGF, which are involved in endothelial migration, proliferation, and increased vascular permeability and can lead to leukocyte recruitment to the atherosclerotic plaque. 27 In line with these results, we show that HCMV-stimulated platelet supernatants were able to induce endothelial tube formation.
Moreover, we show that HCMV-activated platelets expressed and released CD40L. Platelet-derived CD40L is known to mediate the development of atherosclerosis by affecting platelet-platelet, platelet-leukocyte, and leukocyte-endothelium interactions. [28] [29] [30] Furthermore, CD40L induces inflammatory responses in the endothelium, 28 initiates the formation of reactive oxygen species, inhibits nitric oxide production, 31 causes the release of chemokines, and upregulates adhesion receptors and tissue factor. 32 Moreover, sCD40L is involved in Figure 7 . In vivo effects of murine cytomegalovirus (MCMV) on murine platelet activation and neutrophil extravasation. A-D, C57BL/6 mice were intraperitoneally injected with MCMV (2×10 5 pfu) or PBS (100 μL), and after 3 hours, blood was collected. Whole blood was analyzed by flow cytometry for (A) platelet-fibrinogen binding, (B) surface expression of CD40L, and (C) platelet-leukocyte aggregate formation. D, Levels of vascular endothelial-derived growth factor (VEGF) were measured in plasma (n=8 mice per group; *P<0.05 for MCMV vs PBS treatment). E and F, Toll-like receptor (TLR)2 −/− and control mice were intravenously injected with MCMV (2×10 5 pfu) and intraperitoneally injected with 0.5 mL thioglycollate (3%). After 3 hours, neutrophil recruitment into the periotoneum (E) and interleukin-6 (IL-6) release (F) were analyzed. Two independent experiments with a total of 4 to 8 mice. G, Platelet-depleted C57BL/6 were injected with unstimulated platelets or MCMV-stimulated wildtype (w/t) or TLR2 −/− platelets and in vivo platelet-leukocyte aggregate formation was determined. Results from 2 independent experiments (*P<0.05; **P<0.05). H, C57BL/6 mice were platelet depleted, followed by transfusion of MCMV-stimulated platelets from TLR2 −/− and TLR2 +/+ . After 3 hours of thioglycollate stimulation (0.5 mL intraperitoneally), neutrophils in the peritoneum were analyzed. Results of 2 independent experiments are shown. neointima formation and impairs angiogenic peripheral blood outgrowth cells. 33 We also show that HCMV-activated platelets secreted IL-1β that is a key mediator of the inflammatory host response that also exacerbates tissue damage. 34 These observations imply a role for HCMV-platelet interactions in the promotion of both inflammation and angiogenesis.
Animal models have provided solid in vivo evidence linking CMV to the acceleration of vascular disease processes. CMV infection of apolipoprotein E knockout mice leads to aggravated lesion size through local and systemic immune activation. 35 Interestingly, the effect of CMV on plaque development was independent of virus replication and also observed with ultraviolet radiation-inactivated virus, 35 indicating that surface receptor binding is sufficient for these processes. Because platelets are crucially involved in inflammatory and atherogenic processes and able to bind CMV, CMV-platelet interactions might be of high in vivo relevance.
Several lines of evidence point toward a role of TLRs in CMV-induced acceleration of atherogenesis. 36 To date, the extent to which endogenous and exogenous TLR2 agonists contribute to direct platelet activation and proinflammatory and proatherogenic consequences in atherosclerosis is unclear. It has previously been shown that exogenously stimulated bone marrow-derived TLR2 is involved in atherogenesis, 37 but the role of platelet TLR2 has never been investigated in this context. We were able to show in this study that murine cytomegalovirus increased CD40L expression, VEGF release, and platelet-leukocyte aggregate formation in vivo. In a sterile inflamed peritonitis model, we further show that CMV stimulation slightly enhanced neutrophil extravasation. To address the role of platelet-derived TLR2 in CMV infection, we ex vivo stimulated wild-type and TLR2 knockout platelets with CMV and transfused them into platelet-depleted mice. Ex vivo platelet stimulation resulted in in vivo platelet aggregate formation and a tendency to increase neutrophil extravasation in a TLR2-dependent fashion.
Although our study points toward a role for platelets in neutrophil activation and migration, further studies are warranted to elucidate the role of platelets in CMV-induced acceleration of atherogenesis and to determine the contribution of platelet TLR2 to atherosclerotic disease progression.
Taken together, we show that HCMV directly interacts with, and activates, a specific subset of platelets. Although this HCMV-platelet interaction does not induce immediate thrombotic events, it enhances the formation of plateletleukocyte aggregates, promotes neutrophil activation and extravasation, as well as angiogenesis. These processes are critical for immune defense and wound repair, but they can also exacerbate tissue damage and enhance inflammation and atherogenesis. Therefore, the presence of HCMV in the circulation, from either primary infection or periodic viral reactivation, and the subsequent HCMV-platelet interactions could potentially contribute to the effects of HCMV in accelerating atherosclerosis.
In this study, we provide first evidence that human cytomegalovirus (CMV), a well-adapted herpesvirus, activates a subset of platelets via a Toll-like receptor 2-dependent mechanism. Platelet-CMV interaction did not result in platelet aggregation but triggered platelet degranulation, resulting in the release of proinflammatory and proangiogenic responses. On stimulation with CMV, platelets rapidly interacted with leukocytes and enhanced neutrophil activation and transmigration. Supernatants of CMV-stimulated platelets contained high levels of vascular endothelial-derived growth factor and accelerated angiogenic sprouting. In a mouse model, transfusion of ex vivo stimulation of platelets with CMV was sufficient to trigger platelet-leukocyte interactions in vivo, indicating that platelet could contribute leukocyte activation in vivo. These proinflammatory and proangiogenic responses of CMV-stimulated platelets might exacerbate tissue damage and contribute to CMV-associated acceleration of atherogenesis.
Significance
